Research Reference
Cardiogen
Cardiac tetrapeptide bioregulator — cardiovascular health (no validated dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Cardiogen is a short synthetic peptide bioregulator — the tetrapeptide Ala-Glu-Asp-Arg (AEDR) — from the Khavinson family of "peptide bioregulators." It has been described in review work for a proposed role in regulating cardiovascular-cell gene expression tied to inflammaging.
Cardiogen has no clinical-trial-established human dose. The published research is preclinical and mechanistic — review papers and cell-transport modeling, almost entirely from one Russian research group — so every protocol circulating online is community convention extrapolated from the older Khavinson bioregulators, not a validated regimen.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 20 mg vial. Resulting concentration: 10 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.2 mg | 2 units | 0.02 mL | Daily SubQ (10–20 day course)Lower community range |
| 1 mg | 10 units | 0.1 mL | Daily SubQ (10–20 day course)Mid community range |
| 2 mg | 20 units | 0.2 mL | Daily SubQ (10–20 day course)Upper community range |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 20 mg vial with 2 mL bacteriostatic water, the concentration is 10 mg/mL; a 1 mg dose draws to 10 units (0.1 mL). With 4 mL, the concentration is 5 mg/mL; a 1 mg dose draws to 20 units (0.2 mL).
For a 0.2 mg (200 mcg) dose at 10 mg/mL, that is just 2 units — which is why many community sources dilute further for measurable volumes. Gently swirl — do not shake. Refrigerate at 2–8°C and use within 28 days.
Cycling Protocol
Community sources describe Cardiogen the way the older Khavinson bioregulators were used clinically in Russia — as short, repeated low-dose courses (often 10–20 days) rather than continuous daily dosing. The original rationale, drawn from the bioregulator literature, is that short peptides act as transient signals to gene-expression machinery rather than agents needing steady blood levels (Khavinson & Anisimov, 2009). There is no controlled human data establishing an optimal cycle length for Cardiogen, so this is convention, not evidence.
Routes of Administration
Subcutaneous injection is the route community protocols describe. Some bioregulator products are also sold in sublingual/oral-mucosal formats. No published human trial defines a route for Cardiogen specifically.
- Sites: Abdomen, thigh, or other areas with adequate subcutaneous fat, rotating sites across courses
- Volume: Small — at 10 mg/mL even a 1 mg dose is only 0.1 mL
- Because the community dose range is low and uncertain, many users dilute generously so small doses are measurable
Stacking Protocols
There is no human trial data on Cardiogen stacks. Community sources sometimes pair it with other Khavinson bioregulators on a theoretical "different tissue targets" rationale.
| Stack | Rationale | Notes | | --- | --- | --- | | Cardiogen + Cartalax | Pairing tissue-specific bioregulators (cardiac + cartilage) | No data on the combination; community-reported only | | Cardiogen + Epitalon | Broader longevity/geroprotection pairing | Theoretical; no controlled data |
These reflect community theory, not validated combinations.
Side Effects & Safety
- Limited safety data — there is no published human safety dataset for Cardiogen specifically. Community reports describe it as well tolerated at low doses, but that is anecdote, not a safety profile.
- Injection-site reactions — the most commonly mentioned community-reported event (mild redness or irritation), consistent with other subcutaneous peptides.
- Unknown long-term effects — no long-term human exposure data exists.
The short-peptide bioregulator class has a generally benign profile in the preclinical literature, but absence of reported harm in laboratory work is not the same as demonstrated human safety.
Research Basis
The honest answer: the dose numbers do not come from human trials.
The published evidence is preclinical and mechanistic. The strongest Cardiogen-relevant work is a 2022 review describing the AEDR tetrapeptide among peptides that regulate cardiovascular-cell inflammaging and SASP-related molecules (Khavinson et al., 2022, PMID 36611900), plus a 2023 paper modeling how ultrashort peptides are transported into cells (Khavinson et al., 2023, PMID 36979488). Both are mechanistic — neither establishes a human dose.
Community doses are extrapolated. The low-dose, short-course pattern is borrowed from how the original Khavinson tissue bioregulators were used, scaled by analogy and general peptide-handling convention. That is a reasonable starting point for the community, but it is not a tested protocol.
Peptides like ARA-290 or BPC-157 have a specific trial dose to point to. Cardiogen does not — anyone presenting a precise "optimal" Cardiogen dose as established fact is overstating the evidence.